• Online First:
    6articles
    Sort by
    Latest
    Open Access
    Editorial
    Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
    Carminia Maria Della Corte ... Floriana Morgillo
    Online First: April 19, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00041
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:47
    Download:2
    Times Cited: 0
    Open Access
    Original Article
    Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
    Aim: Nuclear factor erythroid 2-related factor 2 (NRF2) is a key component in the cell’s response to oxidative and electrophilic stress and is a transcription factor regulating the expression of a collection of anti-oxidative and cytoprotective genes. Human epidermal growth factor receptor 4 (HER4/erbB4) regulates growth and differentiation in many cancer types. Here, NRF2 and HER4 receptor interactions were investigated in a panel of ovarian cancer cell lines....
    Ibrahim H. Kankia ... Yusuf Y. Deeni
    Online First: April 19, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00040
    View:60
    Download:0
    Times Cited: 0
    Open Access
    Review
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results and an increase in survival rates. However, immune...
    Daniele Balducci ... Luca Maroni
    Online First: April 13, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00039
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:77
    Download:1
    Times Cited: 0
    Open Access
    Review
    Liquid biopsy in NSCLC: a new challenge in radiation therapy
    Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific mole...
    Annarita Perillo ... Ida Rosalia Scognamiglio
    Online First: April 13, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00038
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:103
    Download:9
    Times Cited: 0
    Open Access
    Review
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
    About 15-20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene. Such alterations lead to a more aggressive behavior of the disease, but also predict response to treatments targeting HER2. Indeed, several anti-HER2 compounds have been developed and approved in the last two decades, significantly improving our ability to cure patients in the early setting, and greatly extending their survival in the advanced setting. However, recent evolutions in t...
    Paolo Tarantino ... Giuseppe Curigliano
    Online First: March 23, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00037
    View:584
    Download:27
    Times Cited: 0
    Open Access
    Review
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas...
    Valeria Cognigni ... Rossana Berardi
    Online First: March 08, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00036
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:178
    Download:6
    Times Cited: 0